AXIM Biotechnologies Incorporated (‘AXIM’)
Impression Healthcare recently announced that it has executed a letter of intent and exclusivity agreement with Cannabinoid therapeutics company AXIM Biotechnologies Incorporated (‘AXIM’).
This initiative gives us the opportunity to license and distribute AXIM’s current and future range of products into the Australian and New Zealand markets.
The application process has now formally commenced to obtain licenses from the State Department of Health, Victoria and the Federal Office Of Drug Control (”ODC”) for the importation, storage, distribution and exports of medicinal cannabis products.
The licenses being pursued will allow Impression, subject to individual product permit issue, the capacity to capitalise on local and international opportunities by exporting and importing a wide range of therapeutic cannabis products to generate cash flow.